Trial Outcomes & Findings for Functional Change and Efficacy of Duloxetine in Patients With Co-Morbid Depression & Soft Tissue Discomfort Syndrome (NCT NCT01035073)
NCT ID: NCT01035073
Last Updated: 2020-04-16
Results Overview
COMPLETED
PHASE4
22 participants
Baseline and Week One of Treatment
2020-04-16
Participant Flow
The investigator has succumb to serious health issues which prevents him from physically inputting data in the system. The study team is no longer at the university and despite all efforts to contact them in order to enter data on the investigator's behalf, data are not available.
Participant milestones
| Measure |
Duloxetine
Duloxetine: 30-60 mg daily for 8 weeks
|
|---|---|
|
Overall Study
STARTED
|
0
|
|
Overall Study
COMPLETED
|
0
|
|
Overall Study
NOT COMPLETED
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Functional Change and Efficacy of Duloxetine in Patients With Co-Morbid Depression & Soft Tissue Discomfort Syndrome
Baseline characteristics by cohort
Baseline data not reported
PRIMARY outcome
Timeframe: Baseline and Week One of TreatmentPopulation: The investigator has succumb to serious health issues which prevents him from physically inputting data in the system. The study team is no longer at the university and despite all efforts to contact them in order to enter data on the investigator's behalf, data are not available.
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: Baseline; Week 6 and Week 8 of TreatmentPopulation: The investigator has succumb to serious health issues which prevents him from physically inputting data in the system. The study team is no longer at the university and despite all efforts to contact them in order to enter data on the investigator's behalf, data are not available.
Outcome measures
Outcome data not reported
Adverse Events
Duloxetine
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place